ARKD yields 331.30% · JNJ yields 2.14%● Live data
📍 ARKD pulled ahead of the other in Year 1
Combined, ARKD + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ARKD + JNJ for your $10,000?
ARKD is an actively managed ETF aiming to provide a more tampered price return for shares of ARK Innovation ETF (ticker: ARKK), over a one-year period starting each January. The fund aims to cut the downside risk in half in exchange for a capped upside potential after a 5% performance hurdle is reached. ARKK holds US and foreign equities focused on disruptive innovation themes such as genomics, AI, robotics, fintech. The fund holds shares of ARKK, sells at-the-money calls against the shares, buys at-the-money puts covering 50% of the funds NAV, and buys out-of-the-money calls with any available premium in order to provide upside exposure above the 5% hurdle. All returns are before fees and expenses, which reduce overall fund returns. ARKD shareholders do not receive dividends, if any, from shares of ARKK. The strategy works best for investors willing to hold shares the entire outcome period. Outcomes will differ for those buying/selling mid-period.
Full ARKD Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.